

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Neither this announcement nor any copy thereof may be released into or distributed, directly or indirectly, in the United States or any other jurisdiction where such release or distribution might be unlawful. This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase, or subscribe for any securities of the Company.

This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions where such offer is unlawful. The Company's shares mentioned in this announcement have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the U.S. Securities Act. The Company has no intention to register under the U.S. Securities Act any of the securities referred to herein or to conduct a public offering of securities in the United States.



(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2509)

COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE

Sole Placing Agent



Reference is made to the announcement of Qyuns Therapeutics Co., Ltd. (the "**Company**") dated August 18, 2025 in respect of the placing of new H Shares under general mandate (the "**Placing Announcement**"). Capitalized terms used herein shall have the same meanings as those defined in the Placing Announcement unless otherwise specified.

COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE

The Board is pleased to announce that all the conditions set out in the Placing Agreement have been fulfilled and the Placing Completion took place on August 25, 2025 in accordance with the terms of the Placing Agreement.

A total of 5,000,000 Placing Shares have been successfully placed by the Placing Agent to one placee, namely TruMed Health Innovation Fund LP ("**TruMed**") at the Placing Price of HK\$20.0 per Placing Share pursuant to the terms and conditions of the Placing Agreement, representing (i) approximately 2.25% of the number of issued Shares immediately before Placing Completion; and (ii) approximately 2.20% of the number of issued Shares immediately upon Placing Completion as enlarged by the allotment and issue of the Placing Shares.

The Company wishes to supplement additional information on TruMed.

TruMed is an exempted limited partnership incorporated in the Cayman Islands, and it is a pooled investment fund with sizeable asset under management primarily investing in healthcare equities. The general partner is TruMed Health Innovation Fund GP Limited, which is controlled by Ms. Ting Wang. TruMed has over 35 limited partners who are fund of funds, corporations, family offices and high net wealth individuals, etc. and none of the limited partners holds 30% or more equity interest in TruMed. In this connection, the Company considers that TruMed is a registered investment fund with a wide investor base.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, (i) the Placee and its respective ultimate beneficial owner(s) (where applicable) is an Independent Third Party; and (ii) it is not expected that the Placee will become a substantial shareholder (as defined in the Listing Rules) of the Company immediately after the Placing Completion.

For other details of the Placing, please refer to the Placing Announcement.

EFFECTS OF THE PLACING ON SHAREHOLDING STRUCTURE OF THE COMPANY

Following the Placing Completion and as of the date of this announcement, the number of the total issued Shares of the Company is 227,071,600 H Shares.

The table below sets out a summary of the shareholding structure of the Company (i) immediately before the Placing Completion; and (ii) immediately upon the Placing Completion:

	Immediately before the Placing Completion		Immediately upon the Placing Completion	
	<i>Number of Shares</i>	<i>Approximate percentage of total issued Shares (%)⁽¹⁾</i>	<i>Number of Shares</i>	<i>Approximate percentage of total issued Shares (%)⁽¹⁾</i>
Core connected persons	142,205,400	64.04%	142,205,400	62.63%
Placee	—	—	5,000,000	2.20%
Other H Shareholders	79,866,200	35.96%	79,866,200	35.17%
Total	222,071,600	100%	227,071,600	100%

Note:

(1) The percentages may not add up to subtotal or total due to rounding.

The Directors confirm that, immediately after the Placing Completion, the public float of the Company remains no less than 25% of the Company's issued share capital as enlarged by the Placing.

By order of the Board
Qyuns Therapeutics Co., Ltd.
Mr. Qiu Jiwan
Chairman of the Board and Executive Director

Hong Kong, August 25, 2025

As of the date of this announcement, the Board comprises Mr. Qiu Jiwan as chairman and executive Director, Mr. Wu Yiliang and Mr. Lin Weidong as executive Directors, Mr. Yu Xi and Mr. Wu Zhiqiang as non-executive Directors, and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive Directors.